Targeted analysis of progressive metabolic perturbations in colorectal cancer in colorectal adenoma: Potential for a serum metabolomics-based colorectal cancer screening test.

Authors

null

Farshad Farshidfar

Department of Surgery and Oncology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

Farshad Farshidfar , Aalim Weljie , Karen A. Kopciuk , Hans J. Vogel , Robert Hilsden , Elizabeth McGregor , Oliver F. Bathe

Organizations

Department of Surgery and Oncology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, Institute for Translational Medicine and Therapeutics, University of Pennsylvania and Department of Biological Sciences, University of Calgary, Philadelphia, PA, Departments of Mathematics and Statistics, University of Calgary, and Population Health Research, Alberta Health Services, Calgary, AB, Canada, Biological Sciences Department, University of Calgary, Calgary, AB, Canada, Department of Medicine, University of Calgary and Forzani and MacPhail Colon Cancer Screening Centre, Calgary, AB, Canada, Department of Oncology, University of Calgary and Population Health Research, Alberta Health Services, Calgary, AB, Canada, Department of Surgery and Department of Oncology, University of Calgary, Calgary, AB, Canada

Research Funding

No funding sources reported

Background: Colorectal cancer (CRC) could be resected and cured if detected at an early stage. A serum metabolomics-based screening test would represent a rapid and convenient means to identify adenoma and early CRC. However, changes in the metabolome with such minimal disease may be too subtle if the usual high throughput discovery approach were taken. We postulated that adenoma-associated metabolic changes could be better identified by targeting our analysis to metabolites that changed in a progressive manner with sequential stages of disease. Methods: Sera from patients with locoregional (LR CRC) and metastatic (mCRC) disease (stage I n=21, stage II n=30 , stage III n= 35, stage IVa n=67) and matched controls (n=121) were analyzed by gas chromatography-mass spectrometry (GC-MS). After normalization, batch correction and autoscaling, 249 features were selected. Metabolites that characterized CRC were filtered by identifying those metabolites that increased or decreased in a progressive manner with higher disease stage. Subsequently, sera from 31 adenoma patients and 31 matched controls, collected under standardized conditions prior to colonoscopy and polypectomy, were analyzed by GC-MS. "The variable importance” of metabolites identified in the first analysis were studied. Results: Products of fatty acid metabolism (dodecanoic acid, 2-amino butanoic acid, isocaproic acid, hexadecanoic acid) and urea were among metabolites that were altered more markedly in advanced disease stages. A number of metabolites that changed in this progressive fashion were found to change to a more subtle degree in adenoma. Conclusions: A targeted analysis of metabolites that change in a progressive fashion as CRC progresses represents a means to identify the subtle changes in the serum metabolome that accompany adenoma. This demonstrates the feasibility of developing a serum metabolomics-based screening test for CRC. In addition, extension of this selection approach can be used in other applications where minimal disease is challenging to detect with conventional statistical methods.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Prevention, Diagnosis, and Screening

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 426)

DOI

10.1200/jco.2014.32.3_suppl.426

Abstract #

426

Poster Bd #

A45

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Prospective study of a multi-modal blood-based test for colorectal cancer screening.

First Author: Paloma Peinado

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Enhanced blood-based colorectal cancer screening with improved performance in detection of early stage disease.

First Author: Sven Duenwald